Difficulty In Articulating Description Is Relevant To A Determination Of Indefiniteness
Client Alert | less than 1 min read | 06.12.06
In Xerox Corp. v. 3Com Corp , (No. 04-1470), the Federal Circuit reverses in part, vacates in part and remands the district court's summary judgment of invalidity of U.S. Patent No. 5,596,656 (“the ‘656 patent'). Xerox brought suit against 3COM alleging infringement of the ‘656 patent by the “Graffiti” system used in 3Com's PalmPilot devices. The Federal Circuit, which had previously remanded this case on two separate occasions, finds that the district court erred in concluding the term “sloppiness space” is insolubly ambiguous and thereby invalid. The specification, although not considered as providing a rigorously precise description, is deemed nonetheless to provide adequate guidance, “particularly in light of the difficulty in articulating a more exact standard for the concept.”
Insights
Client Alert | 8 min read | 04.17.26
CMS Finalizes CY 2027 Medicare Advantage and Part D Rule: Key Implications for Plan Sponsors
On April 6, 2026, the Centers for Medicare & Medicaid Services (CMS) published its final rule governing the Medicare Advantage (Part C) and Prescription Drug Benefit (Part D) programs for Contract Year (CY) 2027. The final rule is effective June 1, 2026, with most provisions applicable to coverage beginning January 1, 2027, and marketing and communications changes taking effect October 1, 2026. Beyond payment, the rule pursues a broad deregulatory agenda aligned with Executive Order 14192, reversing marketing and enrollment safeguards introduced in 2023 and easing documentation and reporting obligations, while introducing new program integrity requirements.
Client Alert | 1 min read | 04.17.26
Client Alert | 3 min read | 04.17.26
Client Alert | 2 min read | 04.16.26
